The molecule shows good topical and systemic efficacy in several models of inflammatory diseases and a good pharmacokinetic profile. UR-1505 inhibits lymphocyte proliferation by a novel mechanism. UR-1505’s unique profile may provide an alternative to current medications, overcoming the safety concerns associated with corticosteroids and calcineurin inhibitors.

UR-1505 is being developed for the topical treatment of psoriasis and atopic dermatitis. A phase IIa clinical trial in psoriatic patients has established the product’s efficacy. A phase IIa trial in atopic dermatitis is currently ongoing.

Our outstanding Patent department ensures that our global IP is protected.

The PoC studies are currently being conducted, as soon as they are complete Palau Pharma will be seeking the best possible partners to collaborate with.